An invasive adenocarcinoma confined to the mucosa or mucosa and submucosa of the gastric wall. The regional lymph nodes may or may not be involved. It usually occurs in the lesser curvature. The 5-yea...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on microinvasive gastric cancer is limited due to its rarity and the challenges in systematically studying conditions that affect fewer individuals. The lack of identified genetic factors and inheritance patterns further complicates the understanding of this disease. As research continues to evolve, the hope is that more comprehensive data will emerge, aiding in better characterization and management of this condition.
To navigate your care effectively, consider seeking a gastroenterologist or an oncologist with expertise in gastric cancers. They can provide specialized insights and management strategies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer additional support and information. While there are no patient organizations specifically identified for microinvasive gastric cancer, participating in clinical trials or registries related to gastric cancer may provide valuable opportunities for involvement in research and access to new therapies. Genetic counseling may also be beneficial, especially if you have a family history of gastric cancer.
There are several orphan drugs designated for microinvasive gastric cancer, including ramucirumab and zolbetuximab-clzb, which are FDA-approved. Additionally, various drugs are in development, such as antibody-drug conjugates targeting Claudin 18.2 and novel small molecule inhibitors. While no active clinical trials are currently listed, ongoing research may lead to new treatment options. For further information on clinical studies, you can search ClinicalTrials.gov.
Actionable guidance for navigating care for microinvasive gastric cancer
To navigate your care effectively, consider seeking a gastroenterologist or an oncologist with expertise in gastric cancers. They can provide specialized insights and management strategies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer additional support and information. While there are no patient organizations specifically identified for microinvasive gastric cancer, participating in clinical trials or registries related to gastric cancer may provide valuable opportunities for involvement in research and access to new therapies. Genetic counseling may also be beneficial, especially if you have a family history of gastric cancer.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on microinvasive gastric cancer is limited due to its rarity and the challenges in systematically studying conditions that affect fewer individuals. The lack of identified genetic factors and inheritance patterns further complicates the understanding of this disease. As research continues to evolve, the hope is that more comprehensive data will emerge, aiding in better characterization and management of this condition.
To navigate your care effectively, consider seeking a gastroenterologist or an oncologist with expertise in gastric cancers. They can provide specialized insights and management strategies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer additional support and information. While there are no patient organizations specifically identified for microinvasive gastric cancer, participating in clinical trials or registries related to gastric cancer may provide valuable opportunities for involvement in research and access to new therapies. Genetic counseling may also be beneficial, especially if you have a family history of gastric cancer.
There are several orphan drugs designated for microinvasive gastric cancer, including ramucirumab and zolbetuximab-clzb, which are FDA-approved. Additionally, various drugs are in development, such as antibody-drug conjugates targeting Claudin 18.2 and novel small molecule inhibitors. While no active clinical trials are currently listed, ongoing research may lead to new treatment options. For further information on clinical studies, you can search ClinicalTrials.gov.
Actionable guidance for navigating care for microinvasive gastric cancer
To navigate your care effectively, consider seeking a gastroenterologist or an oncologist with expertise in gastric cancers. They can provide specialized insights and management strategies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer additional support and information. While there are no patient organizations specifically identified for microinvasive gastric cancer, participating in clinical trials or registries related to gastric cancer may provide valuable opportunities for involvement in research and access to new therapies. Genetic counseling may also be beneficial, especially if you have a family history of gastric cancer.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on microinvasive gastric cancer is limited due to its rarity and the challenges in systematically studying conditions that affect fewer individuals. The lack of identified genetic factors and inheritance patterns further complicates the understanding of this disease. As research continues to evolve, the hope is that more comprehensive data will emerge, aiding in better characterization and management of this condition.
To navigate your care effectively, consider seeking a gastroenterologist or an oncologist with expertise in gastric cancers. They can provide specialized insights and management strategies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer additional support and information. While there are no patient organizations specifically identified for microinvasive gastric cancer, participating in clinical trials or registries related to gastric cancer may provide valuable opportunities for involvement in research and access to new therapies. Genetic counseling may also be beneficial, especially if you have a family history of gastric cancer.
There are several orphan drugs designated for microinvasive gastric cancer, including ramucirumab and zolbetuximab-clzb, which are FDA-approved. Additionally, various drugs are in development, such as antibody-drug conjugates targeting Claudin 18.2 and novel small molecule inhibitors. While no active clinical trials are currently listed, ongoing research may lead to new treatment options. For further information on clinical studies, you can search ClinicalTrials.gov.
Actionable guidance for navigating care for microinvasive gastric cancer
To navigate your care effectively, consider seeking a gastroenterologist or an oncologist with expertise in gastric cancers. They can provide specialized insights and management strategies. Resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org can offer additional support and information. While there are no patient organizations specifically identified for microinvasive gastric cancer, participating in clinical trials or registries related to gastric cancer may provide valuable opportunities for involvement in research and access to new therapies. Genetic counseling may also be beneficial, especially if you have a family history of gastric cancer.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 5, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.